Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

BACKGROUND: This phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer. METHODS: Patients were enrolled in four cohorts: MM-302 monotherapy (8, 16, 30, 40, and 50 mg/m(2) ever...

Descripción completa

Detalles Bibliográficos
Autores principales: Munster, Pamela, Krop, Ian E., LoRusso, Patricia, Ma, Cynthia, Siegel, Barry A., Shields, Anthony F., Molnár, István, Wickham, Thomas J., Reynolds, Joseph, Campbell, Karen, Hendriks, Bart S., Adiwijaya, Bambang S., Geretti, Elena, Moyo, Victor, Miller, Kathy D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219487/
https://www.ncbi.nlm.nih.gov/pubmed/30361524
http://dx.doi.org/10.1038/s41416-018-0235-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219487/
https://www.ncbi.nlm.nih.gov/pubmed/30361524
http://dx.doi.org/10.1038/s41416-018-0235-2

Ejemplares similares